Significant Financial Interest (SFI)

A Significant Financial Interest (SFI) is a specific, dollar-threshold-defined category of financial relationship under the U.S. Public Health Service (PHS) financial conflict of interest (FCOI) regulations at 42 CFR Part 50, Subpart F (“Promoting Objectivity in Research”). It is not a synonym for conflict of interest generally — it is the specific, defined trigger that determines whether an institution receiving PHS funding (including NIH) must collect a disclosure from an Investigator and evaluate whether that interest is related to the Investigator’s PHS-funded research. An interest that meets the SFI definition does not automatically mean a conflict exists; it means the institution’s designated official must review it and determine whether it constitutes, or is likely to constitute, a Financial Conflict of Interest (FCOI) requiring a management plan.

Operational definition

Under 42 CFR 50.603, an interest held by an Investigator (and the Investigator’s spouse and dependent children) counts as an SFI when it crosses one of these thresholds in the 12 months preceding disclosure:

• Publicly traded entity: the aggregate of remuneration received (salary, consulting fees, honoraria, paid authorship, equity value at time of disclosure) exceeds $5,000 from that single entity.
• Non-publicly traded entity: remuneration exceeds $5,000, or the Investigator holds any equity interest at all (any value), whichever threshold is met first.
• Intellectual property rights and interests: income received from IP rights (e.g., patents, copyrights) upon receipt of related royalty income.
• Sponsored or reimbursed travel related to the Investigator’s institutional responsibilities, above the institution’s designated threshold (institutions must disclose the purpose, entity, destination, and duration of travel funded or reimbursed by a non-institutional source, unless a regulatory exclusion applies).

The regulation applies to any “Investigator” — defined broadly as anyone responsible for the design, conduct, or reporting of PHS-funded research, not only the named Principal Investigator (42 CFR 50.603).

What does not count as an SFI

42 CFR 50.603 carves out specific exclusions. These are not SFIs regardless of dollar amount:

• Salary, royalties, or other remuneration paid by the Investigator’s own institution to the Investigator, if the Investigator is currently employed or otherwise appointed by that institution (including intellectual-property rights assigned to the institution and agreements to share royalties from such rights).
• Income from seminars, lectures, teaching engagements, or service on advisory committees or review panels for a U.S. federal, state, or local government agency, a U.S. institution of higher education, an academic teaching hospital, a medical center, or a research institute affiliated with a U.S. institution of higher education.
• Ownership interests in a mutual fund or retirement account, so long as the Investigator does not directly control the specific investment decisions in that fund.

This is why SFI review is a threshold-and-exclusion test, not a blanket “any outside income” rule — an Investigator can hold substantial outside income (for example, federal-agency review-panel honoraria) that is explicitly excluded from SFI status by regulation.

Worked examples

Example 1 — crosses the threshold. An Investigator on an NIH R01 award receives $7,500 in consulting fees over the prior 12 months from a privately held biotechnology company whose product is related to the Investigator’s research area. Because the entity is not publicly traded and the remuneration exceeds $5,000, this is an SFI that must be disclosed to the institution, which then determines whether it is related to the PHS-funded research and, if so, whether it constitutes an FCOI requiring a management plan.

Example 2 — equity in a non-public startup. An Investigator holds a 2% founder’s equity stake (current estimated value $1,200) in a non-publicly traded startup commercializing technology adjacent to their federally funded lab work. Even though the dollar value is well under $5,000, the mere fact of holding any equity interest in a non-publicly traded entity meets the SFI threshold under 42 CFR 50.603, and disclosure is required.

Counter-example — excluded by regulation. The same Investigator also receives $2,000 for delivering a guest lecture at another U.S. public university. Because the payer is a U.S. institution of higher education and the activity is a teaching engagement, this income is expressly excluded from the SFI definition under 42 CFR 50.603 regardless of amount, and does not need to be disclosed as an SFI (though institutional policy may still require broader outside-activity reporting for other purposes).

Disclosure timing and institutional process

Under 42 CFR 50.604, Investigators must disclose SFIs to their institution at the time of proposal submission, at least annually thereafter for the life of the award, and within 30 days of discovering or acquiring a new SFI (for example, through purchase, marriage, or inheritance). Once disclosed, the institution’s designated official reviews the SFI under 42 CFR 50.605 to determine whether it is related to PHS-funded research and, if so, whether it constitutes an FCOI; where an FCOI is found, the institution must implement a management plan and report the FCOI to the PHS awarding component before expending further award funds. FCOI training is required before engaging in PHS-funded research and at least every four years afterward.

How SFI relates to Conflict of Interest and Appearance of a Conflict of Interest

SFI, Conflict of Interest, and Appearance of a Conflict of Interest are related but distinct concepts, and conflating them is a common source of confusion in compliance training:

• An SFI is a specific, dollar-defined financial fact that triggers a disclosure obligation — it says nothing on its own about whether the interest actually influences the research.
• A Financial Conflict of Interest (FCOI) exists when the institution determines that a disclosed SFI is both related to the PHS-funded research and could directly and significantly affect its design, conduct, or reporting.
• An Appearance of a Conflict of Interest can exist independently of any SFI threshold being met — it turns on whether a reasonable outside observer could question an Investigator’s objectivity, regardless of dollar amount, and institutions may choose to manage appearance-level concerns even when no formal FCOI determination is triggered.

See also Conflict of Interest Disclosure Form, NIH Conflict of Interest Policy, and Types of Conflict of Interest for how SFI disclosures feed into the broader institutional COI management process.